US FDA grants approval to Bayer's stronger GBCA imaging agent
This article was originally published in Scrip
Executive Summary
Bayer HealthCare Pharmaceuticals won approval in the US for Gadavist (gadobutrol) for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children as young as 2 years to detect and visualize areas with disrupted blood brain barrier (BBB) or abnormal vascularity of the central nervous system (CNS).